 Shawn McCandless
Concepts (392)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 12 | 2020 | 167 | 2.310 |
Why?
| | Prader-Willi Syndrome | 8 | 2024 | 30 | 2.150 |
Why?
| | Urea Cycle Disorders, Inborn | 16 | 2020 | 23 | 2.000 |
Why?
| | Phenylbutyrates | 12 | 2020 | 23 | 1.220 |
Why?
| | Metabolism, Inborn Errors | 6 | 2021 | 40 | 1.090 |
Why?
| | Glycerol | 11 | 2020 | 91 | 1.080 |
Why?
| | Hyperphagia | 4 | 2024 | 40 | 0.840 |
Why?
| | Abnormalities, Multiple | 6 | 2013 | 195 | 0.800 |
Why?
| | Phenylketonurias | 3 | 2023 | 15 | 0.760 |
Why?
| | Ammonia | 9 | 2020 | 61 | 0.740 |
Why?
| | Glutamine | 9 | 2018 | 104 | 0.650 |
Why?
| | Infant, Newborn | 28 | 2022 | 6158 | 0.650 |
Why?
| | Chromosome Deletion | 4 | 2010 | 114 | 0.610 |
Why?
| | Galactosemias | 1 | 2019 | 16 | 0.590 |
Why?
| | Cinnamates | 1 | 2017 | 11 | 0.540 |
Why?
| | Cyclohexanes | 1 | 2017 | 21 | 0.540 |
Why?
| | Aminopeptidases | 1 | 2017 | 22 | 0.540 |
Why?
| | Appetite Depressants | 1 | 2017 | 18 | 0.540 |
Why?
| | Epoxy Compounds | 1 | 2017 | 31 | 0.540 |
Why?
| | Sesquiterpenes | 1 | 2017 | 55 | 0.530 |
Why?
| | Protease Inhibitors | 1 | 2017 | 104 | 0.510 |
Why?
| | Acidosis | 1 | 2017 | 101 | 0.510 |
Why?
| | Genetic Testing | 4 | 2023 | 453 | 0.490 |
Why?
| | Lysosomal Storage Diseases | 1 | 2015 | 5 | 0.480 |
Why?
| | Glycoproteins | 1 | 2017 | 354 | 0.460 |
Why?
| | Public Health | 1 | 2020 | 582 | 0.450 |
Why?
| | Hyperammonemia | 4 | 2020 | 15 | 0.440 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 105 | 0.430 |
Why?
| | Infant | 25 | 2024 | 9577 | 0.420 |
Why?
| | Consanguinity | 1 | 2013 | 49 | 0.410 |
Why?
| | Child, Preschool | 27 | 2024 | 11158 | 0.390 |
Why?
| | Lipid Metabolism, Inborn Errors | 1 | 2012 | 18 | 0.390 |
Why?
| | Hazardous Substances | 1 | 2012 | 17 | 0.390 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2013 | 761 | 0.370 |
Why?
| | Obesity | 2 | 2017 | 2994 | 0.360 |
Why?
| | Amino Acids | 1 | 2015 | 497 | 0.350 |
Why?
| | Humans | 72 | 2024 | 138972 | 0.330 |
Why?
| | Phenylalanine | 4 | 2023 | 68 | 0.330 |
Why?
| | Rare Diseases | 5 | 2019 | 108 | 0.310 |
Why?
| | Child | 30 | 2024 | 21936 | 0.300 |
Why?
| | Phenylacetates | 4 | 2020 | 9 | 0.280 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1159 | 0.270 |
Why?
| | Acyl-CoA Dehydrogenases | 2 | 2024 | 12 | 0.260 |
Why?
| | Adolescent | 22 | 2024 | 21581 | 0.260 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 2138 | 0.260 |
Why?
| | Feeding Behavior | 1 | 2012 | 685 | 0.250 |
Why?
| | Male | 40 | 2024 | 68250 | 0.240 |
Why?
| | Acidosis, Lactic | 2 | 2024 | 46 | 0.240 |
Why?
| | Female | 42 | 2024 | 74016 | 0.240 |
Why?
| | Young Adult | 15 | 2024 | 13371 | 0.230 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2005 | 47 | 0.230 |
Why?
| | Infant Formula | 2 | 2018 | 73 | 0.220 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 42 | 0.220 |
Why?
| | Mutation | 8 | 2019 | 3984 | 0.220 |
Why?
| | Methionine | 2 | 2021 | 159 | 0.220 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.220 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 28 | 0.210 |
Why?
| | Diazoxide | 1 | 2024 | 21 | 0.210 |
Why?
| | Trisomy | 1 | 2005 | 74 | 0.210 |
Why?
| | False Positive Reactions | 2 | 2015 | 124 | 0.210 |
Why?
| | Neutropenia | 2 | 2022 | 157 | 0.210 |
Why?
| | Niacinamide | 1 | 2024 | 82 | 0.210 |
Why?
| | Vitamin B 12 | 2 | 2021 | 125 | 0.210 |
Why?
| | Growth Disorders | 2 | 2019 | 85 | 0.210 |
Why?
| | Genetic Diseases, Inborn | 1 | 2003 | 45 | 0.200 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 178 | 0.200 |
Why?
| | Face | 2 | 2020 | 173 | 0.200 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2022 | 9 | 0.190 |
Why?
| | Mass Spectrometry | 3 | 2004 | 739 | 0.190 |
Why?
| | Phenotype | 7 | 2019 | 3143 | 0.180 |
Why?
| | Leukodystrophy, Metachromatic | 1 | 2001 | 3 | 0.180 |
Why?
| | Cost of Illness | 1 | 2003 | 309 | 0.180 |
Why?
| | Metabolism | 1 | 2021 | 43 | 0.170 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2000 | 19 | 0.170 |
Why?
| | Strabismus | 1 | 2021 | 61 | 0.170 |
Why?
| | Amino Acid Metabolism, Inborn Errors | 2 | 2021 | 25 | 0.170 |
Why?
| | Acyl-CoA Dehydrogenase | 3 | 2012 | 8 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2024 | 325 | 0.170 |
Why?
| | Prenatal Care | 1 | 2023 | 299 | 0.160 |
Why?
| | Hospitals, Pediatric | 1 | 2003 | 516 | 0.160 |
Why?
| | Double-Blind Method | 4 | 2023 | 1949 | 0.160 |
Why?
| | Orphan Drug Production | 1 | 2019 | 5 | 0.160 |
Why?
| | Alleles | 3 | 2019 | 890 | 0.160 |
Why?
| | Adult | 18 | 2024 | 38393 | 0.150 |
Why?
| | Mental Status and Dementia Tests | 1 | 2019 | 25 | 0.150 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2019 | 80 | 0.150 |
Why?
| | DNA Polymerase II | 1 | 2018 | 35 | 0.150 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 33 | 0.150 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2019 | 66 | 0.150 |
Why?
| | Registries | 4 | 2021 | 2081 | 0.150 |
Why?
| | Osteochondrodysplasias | 1 | 2018 | 20 | 0.150 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 428 | 0.150 |
Why?
| | Skin Abnormalities | 1 | 1998 | 12 | 0.150 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1939 | 0.140 |
Why?
| | Eye Abnormalities | 1 | 1998 | 17 | 0.140 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 29 | 0.140 |
Why?
| | Goldenhar Syndrome | 1 | 1998 | 11 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1482 | 0.140 |
Why?
| | Fructose Intolerance | 1 | 2018 | 5 | 0.140 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2018 | 9 | 0.140 |
Why?
| | Fetus | 1 | 2023 | 800 | 0.140 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1998 | 45 | 0.140 |
Why?
| | Endpoint Determination | 1 | 2018 | 78 | 0.140 |
Why?
| | Prodrugs | 1 | 2018 | 46 | 0.140 |
Why?
| | Lipase | 1 | 2018 | 67 | 0.140 |
Why?
| | Exome | 1 | 2019 | 237 | 0.140 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 65 | 0.140 |
Why?
| | Pyruvate Dehydrogenase Complex | 1 | 2017 | 9 | 0.140 |
Why?
| | Pyruvate Dehydrogenase Complex Deficiency Disease | 1 | 2017 | 6 | 0.140 |
Why?
| | Methionyl Aminopeptidases | 1 | 2017 | 1 | 0.140 |
Why?
| | Enzyme Assays | 1 | 2017 | 25 | 0.140 |
Why?
| | Early Termination of Clinical Trials | 1 | 2017 | 18 | 0.140 |
Why?
| | Ketones | 1 | 2017 | 48 | 0.130 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 76 | 0.130 |
Why?
| | Pediatricians | 1 | 2019 | 129 | 0.130 |
Why?
| | Syndrome | 4 | 2020 | 377 | 0.130 |
Why?
| | Glutaryl-CoA Dehydrogenase | 1 | 2016 | 5 | 0.130 |
Why?
| | Brain Diseases, Metabolic | 1 | 2016 | 8 | 0.130 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 135 | 0.130 |
Why?
| | Body Mass Index | 2 | 2017 | 2390 | 0.130 |
Why?
| | Parents | 3 | 2020 | 1423 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 563 | 0.120 |
Why?
| | Patient Preference | 1 | 2018 | 196 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2030 | 0.120 |
Why?
| | Prevalence | 2 | 2012 | 2745 | 0.120 |
Why?
| | Indians, North American | 1 | 2001 | 645 | 0.120 |
Why?
| | Cognition | 2 | 2023 | 1179 | 0.120 |
Why?
| | United States | 6 | 2020 | 15074 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2017 | 190 | 0.110 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2015 | 70 | 0.110 |
Why?
| | Mosaicism | 2 | 2005 | 74 | 0.110 |
Why?
| | Biomarkers | 4 | 2024 | 4095 | 0.110 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2013 | 9 | 0.100 |
Why?
| | Genetic Counseling | 1 | 2014 | 79 | 0.100 |
Why?
| | Hepatic Encephalopathy | 1 | 2013 | 24 | 0.100 |
Why?
| | Genotype | 1 | 2019 | 1849 | 0.100 |
Why?
| | Fibroblasts | 2 | 2017 | 1002 | 0.100 |
Why?
| | Fetal Growth Retardation | 1 | 2018 | 558 | 0.100 |
Why?
| | Rape | 1 | 2013 | 38 | 0.100 |
Why?
| | Cohort Studies | 3 | 2024 | 5744 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2047 | 0.100 |
Why?
| | Ubiquinone | 1 | 2012 | 31 | 0.100 |
Why?
| | Drug Substitution | 1 | 2013 | 56 | 0.100 |
Why?
| | Siblings | 1 | 2013 | 216 | 0.090 |
Why?
| | Mitochondrial Diseases | 1 | 2012 | 91 | 0.090 |
Why?
| | Weight Loss | 1 | 2017 | 783 | 0.090 |
Why?
| | Intellectual Disability | 3 | 2019 | 168 | 0.090 |
Why?
| | Carnitine | 2 | 2003 | 82 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2849 | 0.090 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2010 | 24 | 0.090 |
Why?
| | Urinary Tract | 1 | 1991 | 49 | 0.090 |
Why?
| | Self Report | 1 | 2015 | 842 | 0.090 |
Why?
| | Ectodermal Dysplasia | 1 | 2010 | 18 | 0.090 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2021 | 18 | 0.090 |
Why?
| | Infant, Premature | 1 | 2015 | 580 | 0.080 |
Why?
| | Diaphragm | 1 | 2010 | 43 | 0.080 |
Why?
| | Homocysteine | 2 | 2021 | 154 | 0.080 |
Why?
| | Caregivers | 1 | 2018 | 904 | 0.080 |
Why?
| | Diseases in Twins | 1 | 1991 | 159 | 0.080 |
Why?
| | Vaginal Diseases | 1 | 2010 | 20 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 5884 | 0.080 |
Why?
| | Chromosome Banding | 2 | 2010 | 19 | 0.080 |
Why?
| | Heart Defects, Congenital | 3 | 2010 | 850 | 0.080 |
Why?
| | Risk | 1 | 2012 | 913 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1730 | 0.080 |
Why?
| | Liver | 3 | 2013 | 1807 | 0.080 |
Why?
| | Mental Disorders | 1 | 1998 | 1095 | 0.080 |
Why?
| | alpha-Glucosidases | 1 | 2009 | 9 | 0.080 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2009 | 6 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 135 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 114 | 0.080 |
Why?
| | Middle Aged | 10 | 2021 | 33782 | 0.070 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 195 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5152 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2010 | 286 | 0.070 |
Why?
| | Gene Frequency | 2 | 2016 | 501 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 573 | 0.070 |
Why?
| | Iduronate Sulfatase | 1 | 2006 | 1 | 0.070 |
Why?
| | Mucopolysaccharidosis II | 1 | 2006 | 2 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2010 | 457 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 326 | 0.060 |
Why?
| | Cross-Over Studies | 3 | 2014 | 555 | 0.060 |
Why?
| | Time Factors | 2 | 2015 | 6869 | 0.060 |
Why?
| | Sex Factors | 1 | 2012 | 2050 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2005 | 310 | 0.060 |
Why?
| | Brain | 1 | 1998 | 2791 | 0.060 |
Why?
| | Muscle, Skeletal | 2 | 2013 | 1734 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 638 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 182 | 0.060 |
Why?
| | Karyotyping | 1 | 2005 | 103 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2022 | 15901 | 0.060 |
Why?
| | Chromosome Disorders | 1 | 2005 | 43 | 0.060 |
Why?
| | Fragile X Syndrome | 1 | 2005 | 116 | 0.050 |
Why?
| | Diet | 1 | 2012 | 1285 | 0.050 |
Why?
| | Disease Management | 2 | 2019 | 621 | 0.050 |
Why?
| | Fatal Outcome | 2 | 2010 | 309 | 0.050 |
Why?
| | Radiography | 2 | 2010 | 839 | 0.050 |
Why?
| | Microcephaly | 1 | 2005 | 99 | 0.050 |
Why?
| | Gene Deletion | 1 | 2005 | 389 | 0.050 |
Why?
| | Neuropsychological Tests | 3 | 2019 | 1057 | 0.050 |
Why?
| | X Chromosome | 2 | 2000 | 54 | 0.050 |
Why?
| | Anxiety | 2 | 2023 | 1070 | 0.050 |
Why?
| | Pregnancy | 4 | 2023 | 6870 | 0.050 |
Why?
| | Heterozygote | 2 | 2001 | 306 | 0.050 |
Why?
| | Lymphocytes | 3 | 2017 | 395 | 0.050 |
Why?
| | Hyperhomocysteinemia | 1 | 2003 | 27 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 2962 | 0.050 |
Why?
| | Food, Fortified | 1 | 2003 | 41 | 0.050 |
Why?
| | Carbon-Carbon Ligases | 1 | 2003 | 2 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 253 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 346 | 0.050 |
Why?
| | Cough | 2 | 2017 | 125 | 0.050 |
Why?
| | Pedigree | 2 | 2001 | 510 | 0.050 |
Why?
| | Oxytocin | 1 | 2023 | 52 | 0.050 |
Why?
| | Infant Food | 1 | 2003 | 64 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 591 | 0.050 |
Why?
| | Glucosides | 1 | 2022 | 48 | 0.050 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2022 | 88 | 0.050 |
Why?
| | Developmental Disabilities | 1 | 2005 | 268 | 0.050 |
Why?
| | Benzhydryl Compounds | 1 | 2022 | 75 | 0.040 |
Why?
| | Workflow | 1 | 2023 | 165 | 0.040 |
Why?
| | Founder Effect | 1 | 2001 | 11 | 0.040 |
Why?
| | Homozygote | 2 | 2018 | 202 | 0.040 |
Why?
| | History, 19th Century | 1 | 2001 | 61 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2005 | 430 | 0.040 |
Why?
| | United States Indian Health Service | 1 | 2001 | 45 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 602 | 0.040 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 36 | 0.040 |
Why?
| | Hand Deformities, Congenital | 1 | 2000 | 10 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2000 | 25 | 0.040 |
Why?
| | Facies | 1 | 2000 | 21 | 0.040 |
Why?
| | Warfare | 1 | 2001 | 83 | 0.040 |
Why?
| | Betaine | 1 | 2000 | 64 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 156 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 240 | 0.040 |
Why?
| | Methyltransferases | 1 | 2000 | 72 | 0.040 |
Why?
| | History, 20th Century | 1 | 2001 | 324 | 0.040 |
Why?
| | Nucleocytoplasmic Transport Proteins | 1 | 2019 | 7 | 0.040 |
Why?
| | Vitamins | 1 | 2021 | 188 | 0.040 |
Why?
| | Public-Private Sector Partnerships | 1 | 2019 | 44 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2001 | 335 | 0.040 |
Why?
| | Angelman Syndrome | 1 | 1999 | 11 | 0.040 |
Why?
| | Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2019 | 6 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2018 | 4 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 521 | 0.040 |
Why?
| | Genomic Imprinting | 1 | 1999 | 26 | 0.040 |
Why?
| | Adrenoleukodystrophy | 1 | 1999 | 9 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2879 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5530 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2019 | 130 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2830 | 0.040 |
Why?
| | Urea | 1 | 2019 | 79 | 0.040 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1999 | 61 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2000 | 322 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 353 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 92 | 0.040 |
Why?
| | Executive Function | 1 | 2023 | 453 | 0.040 |
Why?
| | Drug Industry | 1 | 2019 | 109 | 0.040 |
Why?
| | Canada | 1 | 2019 | 408 | 0.030 |
Why?
| | Length of Stay | 1 | 2003 | 1237 | 0.030 |
Why?
| | North America | 1 | 2019 | 304 | 0.030 |
Why?
| | Cleft Lip | 1 | 1998 | 56 | 0.030 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2017 | 10 | 0.030 |
Why?
| | Europe | 1 | 2019 | 407 | 0.030 |
Why?
| | Cleft Palate | 1 | 1998 | 72 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1112 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 1997 | 309 | 0.030 |
Why?
| | Nitrogen | 1 | 2018 | 165 | 0.030 |
Why?
| | Biochemistry | 1 | 2017 | 37 | 0.030 |
Why?
| | Skull | 1 | 1998 | 150 | 0.030 |
Why?
| | DNA Replication | 1 | 2018 | 238 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2006 | 1355 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1998 | 143 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 445 | 0.030 |
Why?
| | Glutarates | 1 | 2016 | 10 | 0.030 |
Why?
| | Lipids | 1 | 2021 | 675 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 433 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 382 | 0.030 |
Why?
| | Cocaine | 1 | 1998 | 173 | 0.030 |
Why?
| | Fever | 1 | 2017 | 305 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 7661 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 1031 | 0.030 |
Why?
| | Child Behavior | 1 | 1998 | 249 | 0.030 |
Why?
| | Cognition Disorders | 1 | 1999 | 511 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 650 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1645 | 0.030 |
Why?
| | North Carolina | 2 | 2006 | 120 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 283 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 2925 | 0.030 |
Why?
| | Primary Health Care | 1 | 2004 | 1776 | 0.030 |
Why?
| | Immunoglobulin G | 2 | 2009 | 898 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 1998 | 538 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 556 | 0.020 |
Why?
| | Enzyme Stability | 2 | 2004 | 72 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2023 | 10921 | 0.020 |
Why?
| | Pediatrics | 1 | 2020 | 1079 | 0.020 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.020 |
Why?
| | DNA Mutational Analysis | 2 | 2005 | 397 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2019 | 754 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2004 | 376 | 0.020 |
Why?
| | Blood Grouping and Crossmatching | 1 | 1991 | 16 | 0.020 |
Why?
| | DNA | 2 | 2010 | 1441 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1701 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 1998 | 816 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2010 | 20 | 0.020 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2010 | 19 | 0.020 |
Why?
| | Chromosome Breakage | 1 | 2010 | 23 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2010 | 29 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3276 | 0.020 |
Why?
| | Muscle Hypotonia | 1 | 2010 | 33 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 1991 | 189 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 769 | 0.020 |
Why?
| | Colpotomy | 1 | 2010 | 2 | 0.020 |
Why?
| | HLA Antigens | 1 | 1991 | 233 | 0.020 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 54 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4182 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3995 | 0.020 |
Why?
| | Glycogen | 1 | 2009 | 55 | 0.020 |
Why?
| | Tracheostomy | 1 | 2010 | 133 | 0.020 |
Why?
| | Pilot Projects | 2 | 2006 | 1765 | 0.020 |
Why?
| | Escherichia coli | 2 | 2004 | 827 | 0.020 |
Why?
| | Body Height | 1 | 2009 | 197 | 0.020 |
Why?
| | Vagina | 1 | 2010 | 193 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1522 | 0.020 |
Why?
| | Skin Diseases | 1 | 2009 | 145 | 0.020 |
Why?
| | Aged | 2 | 2018 | 24172 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 850 | 0.020 |
Why?
| | Glycosaminoglycans | 1 | 2006 | 81 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 897 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7685 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2006 | 60 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 1120 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 695 | 0.020 |
Why?
| | Joints | 1 | 2006 | 107 | 0.020 |
Why?
| | Blood Specimen Collection | 1 | 2006 | 37 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 411 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 2010 | 670 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2005 | 75 | 0.010 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2005 | 86 | 0.010 |
Why?
| | Myristic Acid | 1 | 2004 | 10 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2006 | 561 | 0.010 |
Why?
| | Safety | 1 | 2006 | 348 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 524 | 0.010 |
Why?
| | Histidine | 1 | 2004 | 65 | 0.010 |
Why?
| | Body Weight | 1 | 2009 | 996 | 0.010 |
Why?
| | Circular Dichroism | 1 | 2004 | 150 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2004 | 70 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2152 | 0.010 |
Why?
| | Tyrosine | 1 | 2004 | 227 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 310 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 570 | 0.010 |
Why?
| | Acids | 1 | 2003 | 19 | 0.010 |
Why?
| | Brain Edema | 1 | 2003 | 64 | 0.010 |
Why?
| | Fatty Acids | 1 | 2006 | 445 | 0.010 |
Why?
| | Glutamic Acid | 1 | 2004 | 255 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2850 | 0.010 |
Why?
| | Lysine | 1 | 2004 | 290 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2176 | 0.010 |
Why?
| | Chaperonin 10 | 1 | 2001 | 2 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2001 | 13 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2003 | 144 | 0.010 |
Why?
| | Prion Proteins | 1 | 2000 | 4 | 0.010 |
Why?
| | Betaine-Homocysteine S-Methyltransferase | 1 | 2000 | 9 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2000 | 31 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2000 | 59 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2004 | 1076 | 0.010 |
Why?
| | Prions | 1 | 2000 | 51 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 133 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2000 | 393 | 0.010 |
Why?
| | Exons | 1 | 2001 | 352 | 0.010 |
Why?
| | Amyloid | 1 | 2000 | 95 | 0.010 |
Why?
| | Protein Folding | 1 | 2001 | 276 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2000 | 505 | 0.010 |
Why?
| | Haplotypes | 1 | 2001 | 497 | 0.010 |
Why?
| | Models, Molecular | 1 | 2004 | 1597 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1999 | 55 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1999 | 184 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2687 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 289 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 660 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2000 | 824 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 2159 | 0.010 |
Why?
| | Social Behavior | 1 | 1999 | 292 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 1047 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5591 | 0.010 |
Why?
| | Animals | 3 | 2004 | 37243 | 0.010 |
Why?
| | DNA Methylation | 1 | 1999 | 636 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2001 | 3313 | 0.010 |
Why?
| | Genetic Variation | 1 | 1997 | 990 | 0.010 |
Why?
| | Mice | 2 | 2000 | 17828 | 0.010 |
Why?
| | Disease Progression | 1 | 1999 | 2752 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 3636 | 0.010 |
Why?
|
|
McCandless's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|